Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of camlipixant in adults diagnosed with irritable bowel syndrome with diarrhea IBS-D and mixed irritable bowel syndrome IBS-M. This phase 2b study is designed to compare camlipixant with a placebo in relieving abdominal symptoms. The study includes two parts, with some participants randomly assigned in the second part to receive either a higher dose of the drug or to stop treatment. Participants will receive different doses of camlipixant or placebo during the first part of the study. In the second part, participants may receive either placebo or camlipixant again, allowing researchers to assess the effects of dose adjustments. The dosing levels include three different doses of camlipixant compared with placebo. The study treatment is given under double-blind conditions, meaning neither participants nor researchers know who receives which treatment. Throughout the study, participants will be monitored for changes in abdominal pain intensity and stool consistency over 12 weeks, with safety assessments continuing up to 26 weeks. Researchers will collect data on abdominal pain scores, stool form, global improvement, and any side effects or adverse events. Regular evaluations include physical exams, laboratory tests, and heart monitoring. Participants are expected to be involved in scheduled visits and assessments to track the study outcomes and ensure safety.
Actively Recruiting
Researchers are evaluating depemokimab as a treatment for adults with moderate to severe chronic obstructive pulmonary disease COPD who have type 2 inflammation and uncontrolled symptoms. This Phase 3 study aims to assess the effectiveness and safety of depemokimab when added to standard care for these patients. The focus is on reducing COPD exacerbations and improving respiratory health. Participants will be randomly assigned to receive either depemokimab or a placebo along with their usual COPD treatments. Depemokimab is given as a sterile liquid formulation, and the study compares its effects against placebo over a period of up to 104 weeks. Both groups continue their optimized inhaler therapy during the trial. During the study, participants will undergo regular assessments including lung function tests, symptom questionnaires like the COPD assessment test CAT, and monitoring of exacerbations. Researchers will measure outcomes such as the rate of moderate or severe exacerbations annually and changes in respiratory symptoms. Safety and overall health are closely followed throughout the two-year treatment period.
Actively Recruiting
Researchers are studying the effects of lunsekimig, given as a subcutaneous injection, in adults aged 40 to 80 years with chronic obstructive pulmonary disease COPD that is not well controlled and characterized by an eosinophilic phenotype. This Phase 2bPhase 3, randomized, double-blind, placebo-controlled study compares two dosing regimens of lunsekimig against placebo to evaluate its efficacy, safety, and tolerability over a prolonged period. Participants will be randomly assigned to one of three groups lunsekimig dose regimen A, lunsekimig dose regimen B, or a matching placebo. They will receive subcutaneous injections during a treatment period of about 48 weeks. The study includes a screening phase lasting up to 4 weeks before treatment, followed by an 8-week follow-up after the intervention, totaling up to 60 weeks of participation. During the trial, participants will undergo regular assessments including lung function tests, symptom questionnaires like the Chronic Airways Assessment Test CAAT, and monitoring of exacerbations and adverse events. Researchers will measure the rate of moderate to severe COPD exacerbations as the primary outcome. Safety labs, antibody testing, and drug concentration monitoring will also occur. Participants will be monitored throughout the study duration, including follow-up after treatment ends.
Actively Recruiting
Researchers are studying adolescents aged 12 to under 18 years with asthma who have had at least one severe asthma attack in the past year. This trial compares the effects of two inhalers a combination budesonidealbuterol inhaler and an albuterol-only inhaler, both used as needed. The goal is to see which inhaler better reduces severe asthma exacerbations over one year. Participants will be randomly assigned to use either the budesonidealbuterol inhaler or the albuterol inhaler as needed, in addition to their usual asthma maintenance therapy. The study lasts 52 weeks and includes a 7 to 28 day screening period before treatment and a safety follow-up period of 7 to 14 days after treatment ends. A separate pharmacokinetic sub-study involves a single visit after safety follow-up to evaluate drug levels after one dose of the budesonidealbuterol inhaler. During the study, participants will be regularly monitored for asthma attacks and medication use. Researchers will assess lung function, inhaler technique, and collect safety information including any adverse events. The main outcome is the annual rate of severe asthma exacerbations. Additional measures include time to first severe attack and corticosteroid use. Participants will complete peak flow measurements and have urine pregnancy tests if applicable. The total participation duration is approximately one year plus follow-up.